Kornimate/medical-research-clean huggingface dataset:
high definition profiling of ovarian cancer ascites

Conditions: Ovarian Cancer; High Grade Ovarian Serous Adenocarcinoma; Ascites

Summary: this project entails the collection of a prospective cohort of ascites (as) samples from high grade serous ovarian cancer (hgsoc) patients. high grade serous ovarian cancer (hgsoc) is a major cause of cancer-related mortality, due to the late-stage diagnosis and failure of surgery and chemotherapy (cht) to eradicate the disease with no significant improvement in overall survival. the primary objective of the project is to generate a comprehensive map of ascites cell components, detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid.

hgsoc is a major cause of cancer-related mortality, due to the late-stage diagnosis and failure of surgery and chemotherapy (cht) to eradicate the disease with no significant improvement in overall survival. in recent years, new therapeutic regimens are being tested to improve the care of hgsoc patients. these approaches include the use of poly-adp-ribose polymerase inhibitors (parpi) targeting homology directed repair deficiency, anti-angiogenic drugs, such as anti-vegf monoclonal antibodies, and immune checkpoint inhibitors, that target immune modulation induced by tumor and tumor-associated cells and inflammatory signals. unfortunately, the outcome of such therapies has been to date either erratic or dismal. this points to the acute need to identify new biomarkers predictive of treatment response, effectively geared to the clinical setting. the primary objective of the project is to generate a comprehensive map of ascites cell components, detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid. this will allow to define tumoral archetypes, reflecting hgsoc's endophenotypes, associated with prognosis in patients, possibly guiding future refined therapeutical paradigms for ovarian cancer patients and endowing researchers with a well-characterized multilayered dataset for future reference in the context of molecular dissection and target discovery paradigms. indeed, the combination of origin- and archetype-based stratification of hgsoc patients, will allow to better identify patients for which existing therapeutical regimens could be beneficial, such as the use of checkpoint inhibitors and anti-angiogenic drugs, that have been so far erratic in ameliorating patient's survival.

Eligibility criteria:
inclusion criteria: * patients with suspicious or confirmed ovarian cancer pathology undergoing debulking surgery * diagnosis of high grade serous ovarian cancer confirmed by histopathology assessment * patients who provided written informed consent exclusion criteria: * hiv-positive patients * hbv-positive patients * hcv-positive patients
trilogy stereotactic body radiotherapy for pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study will assess the efficacy of treating locally advanced pancreatic cancer using stereotactic body radiotherapy (using trilogy) and gemcitabine

in this study, we propose to combine stereotactic body radiotherapy (sbrt) with standard gemcitabine chemotherapy. we hypothesize that earlier administration of systemic chemotherapy may prolong the interval to distant progression and improve overall survival in these patients. in this study, we will treat pancreatic cancer patients with locally advanced disease with 3 weeks of gemcitabine, followed by trilogy(tm) sbrt and additional gemcitabine. 30 patients will be accrued to this study at stanford university medical center, the only site participating in this research study. treatment on this protocol requires placement of 3-5 gold (99.9% pure) fiducials for targeting purposes. four to 7 days after placement of the fiducials, patients will then undergo a 4d pancreatic protocol ct scan through the upper abdomen. in addition, an fdg pet scan is required for treatment planning purposes. this imaging set will be processed for radiosurgery, using a modified linac based radiation treatment planning system (eclipsetm). an sbrt treatment plan will be developed based on tumor geometry and location. all patients will receive a single fraction of 25 gy prescribed to the isodose line that completely surrounds the gross pancreatic tumor volume (gtv) as defined by the contrast ct. following sbrt, patients will be monitored clinically and radiographically.

Eligibility criteria:
inclusion criteria:- pancreatic tumors not to exceed 10 cm in greatest axial dimension * histologically confirmed malignancies of the pancreas * unresectable by ct criteria or exploratory laparotomy or laparoscopy * patients with metastatic disease may be treated if they are symptomatic from the primary tumor * performance status of 0, 1, or 2 * no chemotherapy two weeks prior or two weeks following radiosurgery exclusion criteria: * patients who have had prior radiotherapy to upper abdomen * patients receiving any prior pancreatic cancer therapy * children, pregnant, and breastfeeding women, and lab personnel are excluded * uncontrolled intercurrent illnesses * any concurrent malignancy

Keywords: stereotactic body radiotherapy (sbrt) pancreas cancer locally advanced local control gemcitabine
a study of atezolizumab (an engineered anti-programmed death-ligand 1 [pdl1] antibody) to evaluate safety, tolerability and pharmacokinetics in participants with locally advanced or metastatic solid tumors

Conditions: Tumors; Hematologic Malignancies

Summary: this phase i, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (mpdl3280a) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. the study will be conducted in two cohorts: dose-escalation cohort and expansion cohort.


Eligibility criteria:
inclusion criteria: * participants who are 16 to 17 years old would be enrolled after consultation with the medical monitor * histologically or cytologically documented, incurable or metastatic solid tumor or hematologic malignancy that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard curative therapy exists * representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides, with an associated pathology report * adequate hematologic and end organ function * measurable disease per recist v1.1 for participants with solid malignancies. disease-specific criteria for participants with prostate cancer, glioblastoma multiforme (gbm), malignant lymphoma, or multiple myeloma * for women of childbearing potential: agreement to remain abstinent or use contraceptive methods * eastern cooperative oncology group (ecog) performance status of 0 or 1 * for participants who will undergo serial biopsy in dose-escalation cohort, baseline tumor tissue samples should be of core needle biopsies for deep tumor tissue or organs or excisional or punch biopsies for cutaneous or subcutaneous lesions (\>/=5 millimeter \[mm\] in diameter amenable to serial biopsy) exclusion criteria: * known primary central nervous system (cns) malignancy or symptomatic cns metastases * known hypersensitivity to pharmaceuticals produced in chinese hamster ovary cells or any component of the atezolizumab formulation * history or risk of autoimmune disease (for example, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, wegener's granulomatosis, sjögren's syndrome, bell's palsy, guillain-barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis) * history of human immunodeficiency virus (hiv) infection, active hepatitis b (chronic or acute), or hepatitis c infection * signs or symptoms of infection within 2 weeks prior to cycle 1, day 1 * malignancies other than disease under study within 5 years prior to cycle 1, day 1 * participants with prior allogeneic bone marrow transplantation or prior solid organ transplantation
the comparison between traditional laparoscopy-assisted surgery and noses in radical resection of colorectal cancer

Conditions: Laparoscopy-assisted Surgery; Total Laparoscopic Surgery With no Incision (Natural Orifice Transluminal Endoscopic Surgery, NOSES)

Summary: this study is to compare the short-term and long-term outcomes of traditional laparoscopy-assisted surgery and total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, noses) for colorectal cancer and to find a better surgical method for patients.


Eligibility criteria:
inclusion criteria: 1. all cases should be diagnosed as rectal or sigmoid colon cancer by histology or cytology. the tumor is 5-20cm from the pectinate line. the clinical stage is t1-2, n0, m0 for rectal cancer and t1-t3, n0-2, m0 for sigmoid colon cancer. 2. eastern cooperative oncology group (ecog) scale 0-2 3. heart, lung, liver, and kidney function can tolerate operation 4. patients and their families are able to understand and be willing to participate in this clinical study and to sign informed consent. exclusion criteria: 1. history of colorectal malignant disease 2. recent diagnosis of other malignant tumors (except for papillary carcinoma of the thyroid gland and basal cell carcinoma of the skin) 3. patients with intestinal obstruction, intestinal perforation, bleeding requiring emergency surgery 4. a history of abdominal surgery (which makes it difficult to perform laparoscopic procedures), severe systemic disease such as diabetes, severe chronic lung disease, cirrhosis, other malignant diseases 5. combined colorectal multiple carcinomas 6. poor anal function before operation and incontinence of defecation 7. with a history of serious mental illness 8. pregnant or lactating women 9. the researchers believe that the patients are unsuitable to participate in the researchers with other cases. a patient or family refusal to join

Keywords: laparoscopy-assisted surgery noses
hmpl-453 (fgfr inhibitor) in combination with chemotherapy or anti-pd-1 antibody in advanced solid tumors

Conditions: Solid Tumor

Summary: this is a phase ib/ii clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of hmpl-453 combined with chemotherapy or anti-pd-1 antibody in patients with advanced solid tumors.

the study includes a dose escalation phase and a dose-expansion phase. patients with advanced solid tumor will be enrolled in the dose escalation phase to assess the tolerability, safety, and pk profile of hmpl-453 monotherapy or combination therapy. patients with specific types of advanced or metastatic tumors harboring certain fgfr gene alterations will be enrolled in the dose expansion phase to assess the preliminary efficacy of hmpl-453 combination therapy.

Eligibility criteria:
inclusion criteria * dose escalation phase: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumor who progressed on or are intolerant of standard therapy; * dose expansion phase: patients with uc, gc/gej, or ihcc harboring specific fgfr gene alterations; * age 18 to 75 years; * those who are able to give written informed consent, and able to comply with protocol-specified visits and related procedures; * ability to swallow study drug; * ecog ps of 0 or 1; * measurable lesion according to recist v1.1, refer to the protocol; * adequate organ and bone marrow function; * life expectancy ≥ 12 weeks; * female patients or male patients with partners of childbearing potential must take effective contraceptive measures per the protocol. exclusion criteria * patients who previously received selective fgfr targeting therapy; * concurrent participation in another interventional clinical study, excluding those in the follow-up period and have not recently received investigational intervention; * current or previous history of central nervous system (cns) metastases； * current or previous history of retinal detachment； * known history of primary immunodeficiency; * female patients who are pregnant or lactating； * patients who in the opinion of the investigator may be unsuitable for participating in the study; * patients with acute or chronic active hepatitis b or c infection; * known human immunodeficiency virus (hiv) infection and syphilis infection； * clinically significant cardiovascular disease such as congestive heart failure or arrhythmia； * uncontrolled hypertension despite optimal medical management； * received live vaccine within 30 days before the first dose of study drug(s); * those who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to the first study treatment or who are expected to be in need of major surgery; those with unhealed wounds, ulcers or fractures.

Keywords: hmpl-453, fgfr, pd-1,ihcc, icc, gastric cancer
effect of genetic polymorphisms on platinum based chemotherapy in non small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this study evaluate the effect of polymorphism in the excision repair cross-complementing group 5 (ercc5) (rs1047768 and rs751402) gene on the clinical outcome of platinum-based regimens used in the treatment of non-small cell lung cancer (nsclc) patients


Eligibility criteria:
inclusion criteria: 1. newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (nsclc). 2. eastern cooperative oncology group performance status (ecog ps) = 0-2. 3. chemotherapy naïve. 4. age \>18 years. 5. adequate bone marrow reserve exclusion criteria: 1. presence of central nervous system(cns) metastases. 2. inadequate liver function 3. inadequate renal function 4. serious comorbid systemic disorder incompatible with the study. 5. pregnancy

Keywords: non small cell lung cancer nsclc platinum
optimal regimen of patient-controlled epidural analgesia in laboring patients

Conditions: LABOR PAIN

Summary: to test the efficacy of different recipes of epidural infusions used for providing pain relief during labor in parturients.

in this prospective trial, the investigators would like to examine the efficacy of several different pcea protocols in 250 parturients who receive cse for labor pain. any patient with failed epidural, delivery within 2 hours of epidural insertion, or cesarean section will be excluded from the study. each patient will be assigned to one of five groups (a - e), depending on the day of admission for delivery, excluding friday and saturday (observed religious holidays). each group will have 50 patients.

Eligibility criteria:
inclusion criteria: parturients receiving combined spinal epidural analgesia for labor pain relief. exclusion criteria: any patient with failed epidural, delivery within 2 hours of epidural insertion, or cesarean section will be excluded from the study.
effects of repeat inhaled doses of gw597901x on patient safety and lung function in asthmatic subjects

Conditions: Asthma

Summary: this study is designed to look at the safety aspects and effects of repeat inhaled doses of gw597901x in asthmatics to develop this drug for its use in asthma and chronic obstructive pulmonary disease(copd).


Eligibility criteria:
inclusion criteria: * subjects with mild to moderate stable asthma but no other lung problems. * male subjects or female subjects who are not able to get pregnant (e.g. post-menopausal or surgically sterile). * non-smokers. * subjects who show a measurable improvement in the function of their lungs after a single dose of salbutamol. exclusion criteria: * any significant illness. * subjects with heart problems. * subjects who have a cold or chest infection 2-4 weeks prior to the study or have life-threatening asthma. * subjects who take medication for their asthma, or other conditions, not compatible with this study. * subjects who are over sensitive to salbutamol or to ipratropium.

Keywords: gw597901x asthma crossover dose ascending repeat dose inhaled
wallflex esophageal fully covered (fc) benign anastomotic stricture

Conditions: Refractory Anastomotic Esophageal Strictures

Summary: the purpose of this of this study is to compare the safety and effectiveness of temporary indwell of the wallflex esophageal fc metal stent to bougie dilation for the treatment of refractory anastomotic esophageal strictures


Eligibility criteria:
inclusion criteria:esophageal anastomotic stricture post esophagectomy (esophagogastric strictures). * esophagectomy performed at the same institution where patient enrollment and follow-up is planned. * two dilations to at least 16 mm in diameter since esophagectomy. * 1st dilation no more than 6 months post esophagectomy and 2nd dilation within 6 months of 1st dilation to 16mm. * dysphagia score of 2 (ability to swallow semi-solid foods), 3 (ability to swallow liquids only) or 4 (unable to swallow liquids) at baseline. * unable to pass a standard endoscope (approx. 9.8 mm diameter). * age 18 years or older. * willing and able to comply with the study procedures and provide exclusion criteria:stricture within 2 cm of the upper esophageal sphincter. * dysphagia related to motility disorder. * non-anastomotic esophageal strictures. * esophagocolonic strictures. * planned adjuvant radiation therapy post esophagectomy. * prior esophageal stent placements post esophagectomy. * active erosive esophagitis. * sensitivity to any components of the stent or delivery system. * concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. participation in a clinical trial evaluating an investigational device within 3 months prior to enrollment in this study. * stricture length \> 5 cm.

Keywords: refractory anastomotic esophageal strictures
vivo™ accuracy study

Conditions: Premature Ventricular Contraction; Ventricular Tachycardia

Summary: a multi-center study designed to assess the accuracy of vivo™ in determining the location of a pvc/vt foci in comparison to an electroanatomical mapping system.

the vivo accuracy study will assess the accuracy of locating a pvc/vt foci by pacing known anatomical locations and comparing the vivo outcome to that of the carto system (biosense-webster).

Eligibility criteria:
inclusion criteria: * subjects who are at least 18 years or older * subjects who are scheduled for pvc/vt ablation procedure with structurally normal hearts and less than 10% scar. * subjects who have signed an irb/ec approved informed consent form and applicable subject privacy protection authorization per local law * subjects will be selected without regard to gender or age (unless precluded by local regulatory requirements) exclusion criteria: * subjects who are contraindicated for ct or mri (must be able to get one) * subject whose mri or ct scan does not comply with the requirements of this protocol * subjects who are contraindicated for an electrophysiology procedure and/or fluoroscopy: * inr \> 3 * active infection * pregnancy: females of childbearing potential with a positive pregnancy test. * existing mechanical heart valve
elderly dependent patients with non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is in non small-cell lung cancer stage iv et iiib (t4 with pleural effusion) in elderly dependent patients with evaluation of the sequence gemcitabine first line followed by erlotinib when progression versus erlotinib first line followed by gemcitabine when progression

a multicenter phase ii trial,prospective,randomized,open,non comparative

Eligibility criteria:
inclusion criteria: * age \> 65 * comorbidities score, ps and frailty score according to table 1 * no dementia, faecal or urinary incontinence, repeated falls * adl = 0, iadl = 0-1 * life expectancy at least 12 weeks * creatinin clearance \> = 30 ml/mn (according to cockcrofts-gault formula) * competency to give written informed consent * haematological functions as follows : neutrophiles count \> 1.5 x 109/l and platelets \> 100 x 109/l hemoglobin \> 9,5 g/dl - hepatic function as follows : bilirubin \< 1,25 lns asat / alat \<5 x nalcph \<5 x n * ps \< 3 * cerebral metastasis eligible if asymptomatic * histologically or cytologically confirmed nsclc * stage iv/iiib4 (t4 with pleural effusion) * no prior chemotherapy * relapses of previous nsclc treated by surgery or radiotherapy are eligible, if the target is measurable out of initial radiotherapy field and if cytological or histological proof * at least one measurable target lesion by recist guidelines exclusion criteria: * symptomatic cerebral metastasis * any severe comorbidity calculated by charlson score according to table 1 * adl \> 0 and iadl \> 1- performance status \>2 (ecog) * peripheral neuropathy grade 2 or more * dementia, repeated falls, urinary or faecal incontinence * contra-indication to corticosteroids * contra indication to a product of this study * unwilling or unable to comply with study requirements, for personal, family, sociologic, geographic or any other reason * inability of the subject to give written informed consent * lack of liberty following legal or administrative decision * hypersensitivity to polysorbate * hypersensitivity to erlotinib or any excipients of this product * unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of malabsorption in glucose or galactose * participation in concomitant clinical trial * bronchioloalveolar or neuroendocrine or composite carcinoma * superior vena cava syndrome

Keywords: cancer lung cancer none small-cell lung cancer